Skip to main content
25 January 2021
Last updated:
Monday 25 January 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Clinical Research

Merck drops Covid-19 vaccine candidates

Monday 25 January 2021
Country

United States

Merck & Co Inc has dropped development of two candidate Covid-19 vaccines less than a year after bringing them into its portfolio from third parties. The company said both vaccines were well tolerated in Phase 1 studies but generated immune responses that were inferior to those seen from natural infections and responses reported for competitor products.

Read more

Faricimab is non-inferior to aflibercept

Monday 25 January 2021
Country

Switzerland

Faricimab, a bispecific antibody for neovascular age-related macular degeneration, has met its non-inferiority endpoint in two Phase 3 trials, the developer Roche announced on 25 January. The two studies showed that people who were treated with the bispecific antibody at fixed intervals of up to every 16 weeks achieved visual acuity outcomes that were equivalent to those receiving aflibercept, an approved drug, every eight weeks. Effectively this means that patients receiving faricimab would have a longer interval between treatments.

Read more

Trial of ulcerative colitis drug stopped

Saturday 23 January 2021
Country

Australia

A Phase 2 trial of a candidate drug for ulcerative colitis has been stopped early following an interim analysis of data, Immutep Ltd of Australia announced on 21 January. The monoclonal antibody was being developed by GlaxoSmithKline Plc under a licensing agreement with Immutep dating from 2010. GSK is conducting an analysis of safety and efficacy data from the trial to determine the next steps.

Read more

Trial of bintrafusp alfa in lung cancer stopped early

Thursday 21 January 2021
Country

Germany

A Phase 3 trial of a candidate immunotherapy for lung cancer, which was being compared with pembrolizumab, has been discontinued, the sponsor Merck KGaA announced on 20 January. The decision was taken on a recommendation of the trial’s independent data monitoring committee which said the study was unlikely to meet the co-primary endpoint of progression-free survival. The trial is known as [email protected] Lung 037.

Read more

Asthma trial fails to meet endpoint

Wednesday 23 December 2020
Country

United States

A Phase 3 study of a prospective asthma treatment failed to meet its primary endpoint even though a registration trial for the same drug had positive results. The developers, Amgen Inc and AstraZeneca Plc, said the discrepancy may be due to the design of the failed study, but a further analysis of the data is ongoing.

Read more

Clinical hold for gene therapy programme

Tuesday 22 December 2020
Country

Netherlands

The US Food and Drug Administration has placed a clinical hold on uniQure NV’s gene therapy programme in haemophilia B following a possibly related serious adverse event, the company announced on 21 December. The hold affects the company’s pivotal Phase 3 study called HOPE-B which recently reported positive initial data at the annual meeting of the American Society of Hematology (ASH).

Read more

EUA for Moderna Covid-19 vaccine

Saturday 19 December 2020
Country

United States

The US Food and Drug Administration has issued an emergency use authorisation to Moderna Inc for a vaccine for Covid-19 following trial data showing it was 94.1% effective in preventing the disease. The decision comes just a week after the agency issued an emergency authorisation for a vaccine developed by BioNTech SE and its partner Pfizer Inc. Both vaccines are based on messenger RNA (mRNA), a technology never before used in a human vaccine. The two vaccines work by instructing cells in the body to make copies of the SARS-CoV-2 spike protein.

Read more

Delay in Sanofi and GSK Covid-19 vaccine

Friday 11 December 2020

Sanofi SA and its partner GlaxoSmithKline Plc are to test a new antigen formulation for their  Covid-19 vaccine in order to generate a better response from older adults. Assuming all data are positive, the vaccine would be available in the 2021 fourth quarter rather than mid-2021, the companies announced on 11 December 2020.

Read more

AZ-Oxford vaccine trial in The Lancet

Tuesday 8 December 2020
Country

United Kingdom

Astra Zeneca Plc has announced the publication on 8 December of interim Phase 3 data of a Covid-19 vaccine that it is developing with the University of Oxford in The Lancet. The interim analysis for efficacy and safety, as outlined in the article, are in line with previous disclosures, the company said.

Read more

Yescarta shows four-year survival rate of 44%

Tuesday 8 December 2020
Country

United States

An estimated 44% of patients with advanced lymphoma are still alive four years after receiving a single infusion of Yescarta (axicabtagene ciloleucel) for their disease. The new long-term survival data were presented by Gilead Sciences Inc at the annual meeting of the American Society of Hematology (ASH), further illustrating the efficacy of the chimeric antigen receptor (CAR) T cell therapy class.

Read more

Pagination

  • Page 1
  • Next page ››
Subscribe to Clinical Research

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

T-knife appoints Thomas Soloway as chief executive
Thursday January 21 2021
Domainex makes two executive appointments
Thursday January 21 2021
Richard Francis named CEO of Purespring
Tuesday January 19 2021
Klaas Zuideveld becomes CEO of Versameb
Saturday January 16 2021
MorphoSys appoints new CFO
Thursday January 7 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.